Skip to main content

Table 3 Uncorrected and PCR-corrected efficacy estimates, Burkina Faso therapeutic efficacy study, 2017–2018

From: Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018

  Niangoloko Nanoro Gourcy
AL DP DP AL DP DP AL DP DP
28 Days 28 Days 42 Days 28 Days 28 Days 42 Days 28 Days 28 Days 42 Days
Enrolled 120 120 120 120 120 120 120 120 120
Reached study outcome (%) 109 (90.8) 113 (94.2) 112 (93.3) 114 (95.0) 113 (94.2) 112 (93.3) 110 (91.7) 113 (94.2) 113 (94.2)
Day 3 parasitaemia (%) 2 (2.0) 0 (0.0) 0 (0.0) 1 (0.9) 2 (1.8) 2 (1.8) 0 (0.0) 4 (3.5) 0 (0.0)
Early treatment failure (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9) 2 (1.8) 2 (1.8) 0 (0.0) 4 (3.5) 4 (3.5)
Late clinical failure (%) 13 (11.9) 2 (1.7) 4 (3.6) 35 (30.7) 2 (1.8) 16 (14.3) 25 (22.7) 2 (1.8) 11 (9.7)
Late parasitological failure (%) 25 (22.9) 1 (0.9) 9 (8.0) 47 (41.2) 6 (5.3) 22 (19.6) 32 (29.1) 3 (2.7) 20 (17.7)
Recrudescence 8 1 3 22 3 9 24 3 14
Reinfection 23 2 7 55 6 24 29 2 17
No PCR result available 7 0 3 5 1 5 4 0 0
ACPR 71 111 99 31 103 72 53 104 78
% ACPR Uncorrected (95% CI) 65.1 (55.4–74.0) 98.2 (93.8–99.8) 88,4 (80.0–93.7) 27.2 (19.3–36.3) 91.2 (84.3–95.7) 64.3% (54.7–73.1) 48.2 (38.6–57.9) 92.0 (85.4–96.3) 69.0 (59.6–77.4)
% ACPR PCR-Corrected (95% CI) 89.9 (81.0–95.5) 99.1 (95.1–100) 97.1 (91.6, 99.4 57.4 (43.2–70.8) 97.2 (92.0–99.4) 86.7 (77.5–93.2 68.8 (57.3–78.9) 93.7 (87.4.-97.4) 81.3 (72.0–88.5)
Kaplan–Meier cumulative Efficacy
 Uncorrected (95% CI) 65.5 (55.8–73.6) 98.2 (93.1–99.6) 88.5 (88.1–93.2) 27.8 (19.9–36.2) 91.2 (84.2–95.1) 64.3 (54.7–72.4) 48.7 (39.1–57.6) 92.0 (85.1–95.7) 69.1 (59.7–76.7)
 PCR-corrected (95% CI) 91.6 (83.9–95.7) 99.1 (93.9–99.9) 97.2 (91.7–99.1) 74.4 (63.5–82.5) 97.3 (92.0–99.1) 88.7 (80.5, 93.6) 75.6 (65.8–83.0) 93.9 (87.6–97.0) 83.6 (75.2–89.3)
  1. AL artemether lumefantrine, DP dihydroartemisinin piperaquine, CI confidence intervals, PCR polymerase chain reaction, ACPR adequate clinical and parasitological response